The radiation-induced fibrosis (RIF) treatment market focuses on the development and commercialization of therapies aimed at managing fibrotic tissue damage resulting from radiation therapy used in cancer treatment.
RIF is a chronic, progressive condition characterized by excessive connective tissue formation and scarring, commonly affecting the lungs, skin, gastrointestinal tract, breast tissue, and musculoskeletal system. The market is driven by the growing global cancer population, increasing use of radiation therapy, and rising interest in anti-fibrotic therapies, corticosteroids, and emerging biologics.
In 2025, the global radiation-induced fibrosis treatment market is projected to reach approximately USD 79.02 million, with expectations to grow to around USD 144.2 million by 2035, reflecting a Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period.
Key Market Metrics
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 79.02 Million |
| Projected Market Size in 2035 | USD 144.2 Million |
| CAGR (2025 to 2035) | 6.2% |
This growth is driven by the need for long-term post-radiation care, increased awareness among oncologists and patients, and ongoing clinical research into anti-fibrotic agents, stem cell therapies, and immunomodulatory treatments.
Explore FMI!
Book a free demo
Market in North America, specifically USA and Canada has the largest market share due to high number of cancer survivors, high uptake of radiation therapy by cancer patients, and previous access to off-label anti-fibrotics namely pirfenidone and nintedanib.
Research facilities and biotechs are developing targeted treatments, gene editing and fibroblast modulation technologies, while multi-disciplinary oncology networks support the market with rehabilitation and supportive care activities.
Europe is a reimbursement driven and research market where countries like Germany, the UK, France and Sweden are investing into standardizing clinical care and radiation toxicity research.
Public health systems can support symptom control, physical therapy, and balanced approaches to antioxidant, corticosteroid, and angiotensin-converting enzyme (ACE) inhibitor use in selected individuals. And the continent is leading the way in first-phase clinical trials of fibrosis-reversing agents.
Asia-Pacific region will dominate the growth due to rising incidence of cancer, increasing access for radiotherapy and emerging requirements post-treatment care in Japan, China, South Korea and India. Urban hospitals are pursuing oncology rehabilitation, and Japanese and South Korean pharma companies are actively investigating botanicals in combination with anti-inflammatory drugs for use in RIF.
Lack of Standardized Therapy and Late-Stage Diagnosis
The radiation-induced fibrosis (RIF) treatment market shares unique triad issues due to the lack of standard RIF treatment regimens, limited awareness of oncologists, and late-onset RIF symptoms following radiotherapy.
RIF is often underdiagnosed or mixed up with post-treatment neuropathy or fatigue in editor, allowing the opportunity for early treatment to slip away. Moreover, differing responses between patients do not mean that therapy can be targeted: there is huge variability even across cancers (e.g. breast, head & neck, lung), and while the oncogenes in question have the potential to be small molecules, there is no distinction based on whether they are associated with the same/alternate cancer type.
The majority of current therapiessuch as corticosteroids, pentoxifylline, and tocopherol-are symptomatic, and provide only partial relief without any regenerative or anti-fibrotic action. Barriers to reimbursement for off-label drug use, as well as adjunctive therapies, have also hampered market growth.
Lack of Standardized Therapy and Late-Stage Diagnosis
The RIF treatment market is facing significant challenges due to the absence of standard therapeutic guidelines, low awareness among general oncologists, and late-stage diagnosis of symptoms of radiotherapy-induced (RIF) fibrosis. Challenges to recognition and follow up of RIF include its often underreported or confused with nonspecific post-treatment fatigue or neuropathy, with the consequent loss of opportunity to intervene early.
Additionally, the heterogeneity of patient responses, especially among cancer types (e.g., breast, head & neck, lung), further complicates therapy development. Current treatments corticosteroids, pentoxifylline and tocopherol only provide partial symptom improvement without regenerative or anti-fibrotic activity. Another factor that restricts market growth are reimbursement issues associated with off-label drug use and adjunct therapies.
Between 2020 and 2024, RIF treatment was symptomatic and iterative, mainly comprising off-label pharmacological treatment and manual therapy referrals. Patient education was generally poor, and most primary oncology teams lacked specific follow-up protocols for fibrosis.
The model of care delivered will be biologically targeted therapies, digital fibrosis monitoring devices and interdisciplinary rehabilitation models (in cancer center survivorship care programs) between 2025 and 2035. Novel technologies will also emerge in localized delivery platforms, such as implantable anti-fibrotic drug-eluting systems, and in AI-aided fibrosis imaging to improve early detection.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Limited approvals; treatments used off-label for symptom control |
| Technology Innovations | Use of tocopherol, pentoxifylline, corticosteroids, and physical therapy |
| Market Adoption | Concentrated in oncology rehab clinics and academic centers |
| Sustainability Trends | Focus on reducing chronic care costs and disability from late effects |
| Market Competition | Limited to hospital compounding pharmacies and generics |
| Consumer Trends | Demand for pain and stiffness relief after radiotherapy |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Growth in orphan drug designations, EMA/FDA fast tracks for fibrosis-specific therapies |
| Technology Innovations | Emergence of anti-TGF-β drugs, localized gene therapy, cell-based regenerative approaches |
| Market Adoption | Expansion to community oncology settings, survivorship centers, and home-based rehab programs |
| Sustainability Trends | Emphasis on preventive intervention, outpatient care integration, and digital health tracking |
| Market Competition | Entry of biotech startups targeting fibrosis, oncology care coordination platforms, and AI-enabled diagnostics |
| Consumer Trends | Growing demand for quality-of-life restoration, scar tissue reversal, and preventive fibrosis solutions |
The radiation-induced fibrosis treatment market is observing growth, due to the relatively large share of cancer patients treated with radiation therapies. With an increasing number of patients receiving radiotherapy for breast, head & neck, and lung cancers, the incidence of radiation induced fibrosis (RIF) among such patients is rising, particularly in the case of aggressive treatment plans, or multiple courses.
A growing oncology follow-up market, the use of corticosteroids, physical therapy, anti-fibrotic agents and novel biologics all buoy the market. Ongoing studies of targeted therapies and patient rehabilitation programs are also creating demand.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 6.5% |
The UK radiation-induced fibrosis treatment market is growing at a moderate pace, due to improvements in post-cancer care, awareness campaigns and protocols against radiation complications from the National Health Service (NHS).
The shift to carer-centric quality-of-life outcomes in the treatment of cancer has seen the increased use of physiotherapy, hyperbaric oxygen therapy, and novel anti-fibrotic drugs. Multidisciplinary care models including oncologists, rehabilitation therapists and dermatologists are also increasing access to treatment.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 6.0% |
The EMEA (Europe, Middle East, and Africa) Radiation-Induced Fibrosis Treatment market is keeping in view routine usages in countries like Germany, France, and Netherlands where the use of radiotherapy is high. The region has a strong oncology infrastructure and clinical research networks, which can be leveraged to facilitate early identification and treatment of RIF.
Interest in pharmaceutical innovation, especially in the field of anti-inflammatory and collagen-inhibiting agents, is growing. Treatment ecosystems are also being strengthened by EU-wide initiatives on survivor wellness and cross-border collaboration in late-effect management.
| Region | CAGR (2025 to 2035) |
|---|---|
| EU | 5.9% |
Japan’s radiation-induced fibrosis treatment market is growing at a positive rate driven by the increasing geriatric population, rise in cancer survivors and focus on long-term treatment outcomes.
In Japan, oncologists have introduced anti-fibrotic therapies as well as nutritional and physical rehabilitation to provide holistic post-radiation care. At the same time, the growth of minimally invasive radiation therapies, including proton beam therapy, is spurring demand for university-based rather special fibrosis management tools and follow-up protocols.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 6.2% |
South Korea's market for treatment of radiation-induced fibrosis is steadily rising due to an increase in cancer survivorship tracking as well as improvements in the modernization of care. Such as Physical Therapy, Drug management, and digital rehabilitation platforms, integrated post-radiation therapy programs are being setup by plenty of public and private healthcare providers as well.
The evolution of biotechnology and government attention in cancer-related industry have been driving targeted treatments and therapeutic regimens to prevent the or at least slow down the progression of fibrosis.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 6.4% |
| Segmentation type | Market Share (2025) |
|---|---|
| Immunotherapy | 39.4% |
The immunotherapy based RIF therapy market is anticipated to hold the top segment, owing to the revolutionary approach of using the body's own immune system to stop fibrotic pathways. Its mechanism of action is targeted and may lead to reducing side effects and enhance patients’ outcomes.
Research and clinical trials continue to show promising results that are leading to increased use among health care professionals. Monoclonal antibodies and checkpoint inhibitors have also expanded the therapeutic armamentarium and provide new tools for effective RIF’s treatment.
The major portion of RIF’s treatment is from anti-fibrotic drugs. Anti-fibrotic drugs work by antagonizing the biochemical pathways leading to fibrosis, thereby retarding the disease process. As per the study, drugs such as pirfenidone and nintedanib are effective in other fibrotic diseases and are considered for use in RIF Management.
However, recent advances in our understanding of fibrotic mechanisms have led to the development of these focused therapies with the potential to improve outcomes. However, widespread use is constrained by challenges including high cost of treatment and adverse effect profiles.
The intravenous administration of pooled antibodies to modulate immune responses is known as immunoglobulin treatment; and this concept has been explored therapeutically in the context of autoimmune-associated fibrosis.
Immunoglobulins may not be the first-line treatment for RIF, but some patients may benefit from immune modulation. Their niche usage and cost also contributes to their reduced market share.
| Segmentation type | Market Share (2025) |
|---|---|
| Oral | 45.2% |
RIF’s treatments are mainly administered orally, which is popular for its simplicity and non-invasive nature, and increases patient compliance. Oral formulation, as for some anti-fibrotic and immunomodulatory drugs, allow home administration and reduce the need for hospital visits. Drug research targeted the creation of effective oral drugs that is to find efficacy without significant side effects.
The RIF’s treatment market is dominated by injectable therapies. Here, we have biologics and some immunotherapies that have to be given parenterally to get their bioavailability. Injections may be administered in clinics or at home, with adequate training, but they are generally considered more inconvenient than oral therapies.
However, injectable are very important options for patients with advanced RIF or for patients with poor response to oral treatments. For injectable options, new drug formulation and delivery systems, such as long-acting injectable, are intended to enhance patient comfort and adherence, so that injectable therapies can be used for extended duration.
Topical treatments involve applying creams or gels to affected areas to reduce localized fibrosis symptom. While topical preparations enable a more non-invasive approach with negligible systemic absorption, the efficacy of such agents in treating RIF is minuscule compared to systemic treatments.
They are most commonly used as adjuncts to other therapies with the added advantage of providing symptomatic control for dermatologic manifestations of fibrosis. Research is still ongoing for the establishment of more potent topical formulations.
With the increasing use of radiation therapy in cancer treatment and its subsequent long-term complications, the global radar on the Radiation-Induced Fibrosis (RIF) Treatment Market industry is rapidly unfolding.
RIF is a chronic and often irreversible condition that occurs in soft tissue and organs after radiotherapy and can manifest as chronic pain, organ dysfunction, and impaired quality of life. Key market movers are increasing survivorship in oncology, advances in anti-fibrotic agents, stem cell-based therapies and supportive care programs in post-cancer rehabilitation.
Market Share Analysis by Key Players
| Company/Organization Name | Estimated Market Share (%) |
|---|---|
| Merck KGaA | 18-22% |
| Sanofi S.A. | 14-18% |
| Bristol-Myers Squibb | 12-16% |
| Galecto, Inc. | 10-14% |
| Trevi Therapeutics, Inc. | 8-12% |
| Others | 26-32% |
| Company/Organization Name | Key Offerings/Activities |
|---|---|
| Merck KGaA | In 2025, Merck launched a clinical trial for anti-TGFβ monoclonal antibody therapy, aiming to suppress the fibrotic cascade in patients post head, neck, and thoracic radiotherapy. |
| Sanofi S.A. | As of 2024, Sanofi continued development of Pirfenidone-an anti-fibrotic agent repurposed for off-label use in radiation-induced lung and breast fibrosis, supported by real-world evidence. |
| Bristol-Myers Squibb | In 2023, BMS advanced its anti-inflammatory and immunomodulatory drug candidates through phase II trials, focusing on RIF’s prevention following pelvic and abdominal radiotherapy. |
| Galecto, Inc. | In 2024, Galecto completed a phase I/II study of GB0139, a small molecule galectin-3 inhibitor that has shown promise in pulmonary and hepatic fibrosis induced by radiation. |
| Trevi Therapeutics, Inc. | As of 2024, Trevi began preclinical evaluation of oral Nalbuphine ER, aiming to alleviate fibrotic pain and sensory neuropathy resulting from radiotherapy complications. |
Key Market Insights
Merck KGaA (18-22%)
Merck is at the forefront of targeted biologic therapies for fibrosis, with its TGF-β pathway inhibitors showing potential in modulating radiation-induced tissue damage and fibrotic remodelling.
Sanofi S.A. (14-18%)
Sanofi leads in the anti-fibrotic drug space with its work on Pirfenidone and similar compounds, supporting expanded indications in RIF, particularly for breast, lung, and esophageal cancer survivors.
Bristol-Myers Squibb (12-16%)
BMS leverages its immunology and oncology expertise to explore anti-inflammatory strategies for radiation-induced fibrosis, with pipeline assets targeting chronic post-radiotherapy complications.
Galecto, Inc. (10-14%)
Galecto focuses on molecular fibrosis inhibition, with GB0139 offering a novel mechanism of action and potential for application in radiation-induced lung fibrosis and rare organ-specific fibrotic syndromes.
Trevi Therapeutics, Inc. (8-12%)
Trevi targets the neurological and pain-related symptoms of radiation fibrosis through central-acting modulators, opening new avenues for symptom control and quality-of-life improvement.
Other Key Players (26-32% Combined)
Several biotech firms, research institutions, and specialty pharma companies are innovating in fibrosis biology, anti-inflammatory drug design, and regenerative tissue therapies, including:
The overall market size for radiation-induced fibrosis treatment market was USD 79.02 million in 2025.
The radiation-induced fibrosis treatment market is expected to reach USD 144.2 million in 2035.
Rising number of cancer survivors undergoing radiation therapy, increasing research in anti-fibrotic drugs, and growing demand for effective post-radiation care solutions will drive market growth.
The top 5 countries which drives the development of radiation-induced fibrosis treatment market are USA, European Union, Japan, South Korea and UK
Oral administration expected to grow to command significant share over the assessment period.
The Intraoperative Radiation Therapy Systems Market Is Segmented by Disease Indication and End User from 2025 To 2035
The Soft Tissue Repair Market is segmented by Synthetic, Allograft, Xenograft and Alloplast from 2025 to 2035
At Home Heart Health Testing Market Analysis - Size & Industry Trends 2025 to 2035
Eyelid Scrub Market Analysis & Forecast by Product, Application and Region 2025 to 2035
Protein Diagnostics Market Share, Size and Forecast 2025 to 2035
Intraoperative Fluorescence Imaging Market Report - Demand, Trends & Industry Forecast 2025 to 2035
Radiation-Induced Fibrosis Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
